Back to Search Start Over

Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.

Authors :
Kreutz RP
Stanek EJ
Aubert R
Yao J
Breall JA
Desta Z
Skaar TC
Teagarden JR
Frueh FW
Epstein RS
Flockhart DA
Source :
Pharmacotherapy [Pharmacotherapy] 2010 Aug; Vol. 30 (8), pp. 787-96.
Publication Year :
2010

Abstract

Study Objective: To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement.<br />Design: Population-based, retrospective cohort study.<br />Data Source: National medical and pharmacy benefit claims database comprising approximately 19 million members.<br />Patients: A total of 16,690 patients who had undergone PCI with stent placement and who were highly adherent to clopidogrel therapy alone (9862 patients) or to clopidogrel with a PPI (6828 patients) between October 1, 2005, and September 30, 2006.<br />Measurements and Main Results: The primary end point was the occurrence of a major adverse cardiovascular event during the 12 months after stent placement. These events were defined as hospitalization for a cerebrovascular event (stroke or transient ischemic attack), an acute coronary syndrome (myocardial infarction or unstable angina), coronary revascularization (PCI or coronary artery bypass graft), or cardiovascular death. A composite event rate was compared between patients who received clopidogrel alone and those who received concomitant clopidogrel-PPI therapy. Baseline differences in covariates were adjusted by using Cox proportional hazards models. In the 9862 patients receiving clopidogrel alone, 1766 (17.9%) experienced a major adverse cardiovascular event compared with 1710 patients (25.0%) who received concomitant clopidogrel-PPI therapy (adjusted hazard ratio 1.51, 95% confidence interval 1.39-1.64, p<0.0001). Similar associations of increased risk were observed for each PPI studied (omeprazole, esomeprazole, pantoprazole, and lansoprazole).<br />Conclusion: Concomitant use of a PPI and clopidogrel compared with clopidogrel alone was associated with a higher rate of major adverse cardiovascular events within 1 year after coronary stent placement.

Details

Language :
English
ISSN :
1875-9114
Volume :
30
Issue :
8
Database :
MEDLINE
Journal :
Pharmacotherapy
Publication Type :
Academic Journal
Accession number :
20653354
Full Text :
https://doi.org/10.1592/phco.30.8.787